← The Wire
DRTSNasdaq
Alpha Tau Medical Ltd.
Surgical & Medical Instruments & Apparatus · L3 · CIK 1871321
Alpha Tau Medical Ltd. brings innovative Alpha DaRT technology to cancer patients worldwide
$1.08B
Market cap
$11.92
Last close
+1.1%
1D
-2.4%
5D
330K
Volume
Price$11.92+294.7%· 1Y
Volume
Aug 4L $3.02 · H $13.57Aug 3
Fundamentals & quality
Fundamentals not yet available for this company.
Insider activity
Open-market buys & sells (Form 4) · trailing 12 months
0 bought · 1 sold
Net insider $ · by month
buys ▲ · sells ▼
Levy RaphiC-suite
Chief Financial Officer
Sold$268K
2 sells
Open-market buys & sells (Form 4, transaction codes P/S), aggregated per insider over the trailing 12 months. Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance
Filings archive
Newest first · each with a one-line AI read · showing 10 of 132Jul 21, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. reported positive data from a study of Alpha DaRT® in combination with Pembrolizumab for head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival. This result surpassed the study's pre-specified threshold for success.Jun 25, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. held its Annual General Meeting of Shareholders on June 23, 2026, where shareholders approved several proposals including the re-election of directors, re-approval of the executive compensation policy, and the re-appointment of the independent registered public accounting firm.Jun 23, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the successful treatment of the first recurrent glioblastoma patient outside the United States using its Alpha DaRT® technology at Hadassah University Medical Center in Israel. This marks a significant step in the global expansion of their treatment.Jun 11, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced it received FDA clearance to complete enrollment in its REGAIN trial for recurrent glioblastoma and add two U.S. clinical sites, with early interim results showing 100% local disease control.Jun 3, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. entered into a U.S. commercialization agreement for Alpha DaRT for prostate cancer with Tolmar International Ltd., including an initial $15.0 million payment and up to $161.5 million in milestone payments, and concurrently raised $20.0 million in a private placement of its ordinary shares.Jun 1, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced strong overall survival results from its Alpha DaRT® Pancreatic Cancer Studies presented at the 2026 ASCO Annual Meeting. The company filed this report on June 1, 2026.May 18, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. is holding its annual general meeting of shareholders on June 23, 2026, to vote on various proposals. The meeting will take place at the Company's headquarters in Jerusalem, Israel.May 18, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced its first quarter 2026 financial results and provided a corporate update on May 18, 2026. The filing does not contain specific financial results or a headline event beyond the announcement itself.May 11, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. presented interim clinical data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM) during a conference call and webcast on May 11, 2026. The presentation, containing this data, was also made available on the Company's website.May 11, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced positive interim results from its U.S. Alpha DaRT trial for recurrent glioblastoma, showing a 67% complete response rate across the initial patient cohort. The trial observed only one grade 3 serious adverse event that resolved with treatment.
Show 50 more ↓
May 8, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced it will host a conference call on May 8, 2026, to discuss interim results from its first three patients treated for recurrent glioblastoma.May 8, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the completion of patient enrollment in its U.S. pivotal skin cancer study, a key step towards potential FDA approval of its Alpha DaRT® treatment for recurrent cutaneous squamous cell carcinoma. This update was provided in a press release dated May 8, 2026.May 7, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the successful treatment of the first pancreatic cancer patient in Italy using its Alpha DaRT technology at the University of Verona's Pancreas Institute. This marks a significant step in the clinical application of their innovative cancer treatment.May 5, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced upcoming presentation of study results for its Alpha DaRT® technology in combination with Pembrolizumab for head and neck cancer at the AHNS 12th International Conference on Head and Neck Cancer.May 4, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced positive results from its Alpha DaRT pancreatic cancer trials presented at DDW 2026, showing a 100% local disease control rate and a favorable safety profile.Apr 27, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced on April 27, 2026, that it will present data from three Pancreatic Cancer studies utilizing its Alpha DaRT technology at the upcoming ASCO Annual Meeting. This announcement was made via a press release filed as an exhibit to a Form 6-K.Apr 23, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced two significant clinical trial updates: the successful treatment of the first pancreatic cancer patient in Europe using Alpha DaRT® in the ACAPELLA trial, and FDA approval to expand the IMPACT trial to include pancreatic cancer patients receiving specific chemotherapy.Mar 31, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the first-ever oral presentation of its Alpha DaRT® Pancreatic Cancer data at Digestive Disease Week (DDW) 2026. This announcement was made via a press release on March 31, 2026.Mar 9, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced its full year 2025 financial results and provided a corporate update. The filing is a Report of Foreign Private Issuer (Form 6-K) for the month of March 2026.Mar 9, 202620-FANNUAL REPORTAlpha Tau Medical Ltd. reported a net loss of $42,627 for the fiscal year ended December 31, 2025, an increase from $31,750 in 2024, as the company continues to invest heavily in research and development of its Alpha DaRT technology for solid tumors. The company secured approximately $45.5 million in net proceeds from equity issuances in 2025 to fund its operations and growth strategy.Feb 24, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced on February 24, 2026, that it received Japanese marketing approval for its Alpha DaRT® product for unresectable locally advanced or locally recurrent head and neck cancer. This announcement was made via a press release attached to the Form 6-K.Jan 29, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. issued a letter to shareholders on January 29, 2026, highlighting five concurrent trials in the U.S. with multiple significant value-driving milestones ahead.Jan 6, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced positive results from its Pancreatic Cancer Alpha DaRT® Study in two upcoming presentations at the ASCO GI 2026 Symposium, showcasing immune-preservation and high disease control.Jan 5, 20266-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced it submitted its first Pre-Market Approval Module to the FDA for its Alpha DaRT® technology for the treatment of recurrent cutaneous squamous cell carcinoma. This submission marks a significant step in the regulatory approval process for the Company's cancer treatment.Dec 18, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced it will present at the J.P. Morgan 2026 Healthcare Conference. This announcement was made via a press release on December 18, 2025.Dec 9, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the successful treatment of the first patient in its U.S. trial for recurrent glioblastoma at The Ohio State University. This marks a significant step in the company's clinical development for this indication.Dec 4, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the presentation of two abstracts regarding its Alpha DaRT technology for pancreatic cancer at the upcoming 2026 ASCO GI Symposium. This announcement was made via a press release on December 4, 2025.Dec 2, 20256-KFORM 6-KAlpha Tau Medical Ltd. announced it received FDA approval to initiate a trial for patients with locally recurrent prostate cancer. The company filed this announcement on December 2, 2025.Nov 20, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced its third quarter 2025 financial results and provided a corporate update. The filing does not contain specific financial results or a headline event.Oct 21, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced it received a radioactive material license for its New Hampshire manufacturing facility. This license is crucial for the company's production capabilities.Sep 2, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced the successful treatment of the first patient in its U.S. multi-center pancreatic cancer clinical trial. This marks a significant milestone in the company's ongoing research and development efforts.Aug 27, 20256-KREPORT OF FOREIGN PRIVATE ISSUERAlpha Tau Medical Ltd. announced its participation in five investor conferences in September. The company is a foreign private issuer filing a Form 6-K.Aug 11, 20256-KREPORT OF FOREIGN PRIVATE ISSUERJun 17, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMay 28, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMay 19, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMay 13, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMay 12, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMay 6, 20256-KREPORT OF FOREIGN PRIVATE ISSUERApr 28, 20256-KREPORT OF FOREIGN PRIVATE ISSUERApr 28, 2025424B5PROSPECTUS SUPPLEMENTApr 2, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMar 12, 20256-KREPORT OF FOREIGN PRIVATE ISSUERMar 12, 202520-FANNUAL REPORTFeb 27, 20256-KREPORT OF FOREIGN PRIVATE ISSUERFeb 24, 20256-KREPORT OF FOREIGN PRIVATE ISSUERFeb 3, 20256-KREPORT OF FOREIGN PRIVATE ISSUERJan 27, 20256-KREPORT OF FOREIGN PRIVATE ISSUERDec 18, 20246-KCURRENT REPORTDec 17, 20246-KREPORT OF FOREIGN PRIVATE ISSUERDec 17, 20246-KREPORT OF FOREIGN PRIVATE ISSUERDec 11, 20246-KREPORT OF FOREIGN PRIVATE ISSUERDec 6, 20246-KREPORT OF FOREIGN PRIVATE ISSUERNov 19, 20246-KREPORT OF FOREIGN PRIVATE ISSUERNov 13, 20246-KREPORT OF FOREIGN PRIVATE ISSUERNov 12, 20246-KREPORT OF FOREIGN PRIVATE ISSUEROct 21, 20246-KREPORT OF FOREIGN PRIVATE ISSUEROct 10, 20246-KREPORT OF FOREIGN PRIVATE ISSUERSep 20, 20246-KREPORT OF FOREIGN PRIVATE ISSUERAug 22, 20246-KREPORT OF FOREIGN PRIVATE ISSUER